IP Library › Granted Patent US 12,685,798
Granted Patent B2
US 12,685,798 · App. 17/428,256 · Granted Jul 21, 2026

Wound contact layer and dressing for iodine delivery

Inventors: Anthony Dagger (York, GB); Victoria Jody Hammond (Hull, GB); Amy Nicole Wheldrake (Bristol, GB)
Assignee: T.J.Smith and Nephew, Limited
A61L15/26A61L15/30A61L15/44A61L15/60C08L71/02C08L83/04A61L2300/106A61L2300/404
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,685,798
App. No.
17/428,256
Filed
Aug 3, 2021
Granted
Jul 21, 2026
Kind
B2
Art Unit
1615
USPC
424/447
Abstract

Disclosed embodiments relate to a wound contact layer in the form of a perforated film, possessing one or more of the following functions: speed of kill, sustained kill, broad-spectrum kill against microorganisms, one-piece removal, conformability with a wound surface, compatibility with negative pressure wound treatment, exudate management, autolytic debridement, and self-indicating of changes. The wound contact layer comprises a biocompatible polymeric matrix and, embedded in the matrix, fluid-absorbent particles loaded with therapeutics. The matrix comprises a mixture of an elastomeric composition and a hydrophilic polymer. The film is perforated with an array of holes. A desired loading of therapeutics in the wound contact layer may be tuned by varying the amount of therapeutics loaded within the fluid-absorbent particles, the density of the fluid-absorbent particles within the wound contact layer, the perforation size, and the thickness of the wound contact layer.

Claims (28)

1 . A therapeutic composition, comprising:

a single layer matrix, the matrix comprising:

an elastomeric composition comprising a room temperature vulcanizing silicone; and

a hydrophilic polymer;

a plurality of fluid-absorbent particles embedded in the matrix, individual fluid-absorbent particles configured to swell upon contact with fluid and comprising a crosslinked polymer loaded with an iodine-based antimicrobial agent-powder;

wherein the hydrophilic polymer is configured to form a hydrophilic phase in the matrix, the hydrophilic phase configured to provide a pathway for fluid to travel to the fluid-absorbent particles.

2 . The therapeutic composition of claim 1 , wherein the elastomeric composition comprises between about 10% and about 90% by weight of the composition.

3 . The therapeutic composition of claim 1 , wherein the elastomeric composition comprises one or more silicones.

4 . The therapeutic composition of claim 1 , wherein the elastomeric composition comprises an addition curing room temperature vulcanizing (RTV) silicone made from a mixture of at least one elastomeric composition base and at least one curing agent.

5 . The therapeutic composition of claim 1 , wherein the hydrophilic polymer comprises a polyethylene glycol (PEG).

6 . The therapeutic composition of claim 1 , wherein the PEG comprises an average molecular weight in the range from about 200 to about 1,000 g/mole.

7 . The therapeutic composition of claim 5 , wherein the PEG comprises 20% or less by weight of the composition.

8 . The therapeutic composition of claim 1 , wherein the crosslinked polymer comprises a crosslinked polysaccharide.

9 . The therapeutic composition of claim 1 , wherein the fluid-absorbent particles comprise spherical beads.

10 . The therapeutic composition of claim 1 , wherein the fluid-absorbent particles comprise a diameter of less than 1 mm.

11 . The therapeutic composition of claim 1 , wherein the fluid-absorbent particles comprise between about 30% and about 90% by weight of the composition.

12 . The therapeutic composition of claim 1 , wherein the fluid-absorbent particles comprise preferably between about 50% and about 63% by volume of the composition.

13 . The therapeutic composition of claim 1 , wherein the fluid-absorbent particles comprise cadexomer iodine.

14 . The therapeutic composition of claim 1 , wherein the iodine-based antimicrobial agent comprises less than 2% by weight of the fluid-absorbent particles.

15 . A wound contact layer made from the therapeutic composition of claim 1 .

16 . A wound dressing comprising a layer made from the therapeutic composition of claim 1 .

17 . A multi-care wound contact layer, comprising: a flexible, biocompatible layer having an upper surface and a lower surface defining a thickness there between and an array of holes extending at least partially through the thickness, wherein the flexible, biocompatible layer comprises openings, individual openings adjacent to a plurality of individual internal walls, the layer comprising a single layer matrix, the matrix comprising: a room temperature vulcanizing silicone elastomeric composition and a hydrophilic polymer, wherein the hydrophilic polymer is configured to form a hydrophilic phase in the matrix, the hydrophilic phase configured to provide a pathway for fluid to travel to the fluid-absorbent particles; and a plurality of fluid-absorbent particles embedded in the matrix that are configured to swell upon contact with fluid, individual fluid-absorbent particles comprising a crosslinked polymer loaded with an iodine-based antimicrobial agent powder.

18 . The multi-care wound contact layer of claim 17 , wherein the hydrophilic polymer comprises polyethylene glycol (PEG).

19 . The multi-care wound contact layer of claim 17 , wherein the flexible, biocompatible layer comprises, by weight:

10-90% elastomeric composition;

1-20% hydrophilic polymer; and

30-90% fluid-absorbent particles.

20 . The multi-care wound contact layer of claim 17 , wherein the iodine-based antimicrobial agent comprises less than 2% by weight of the fluid-absorbent particles.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2022
From: DAGGER, ANTHONY; HAMMOND, VICTORIA JODY
To: T.J.SMITH AND NEPHEW,LIMITED
Reel/Frame 060689/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 1, 2022
From: DAGGER, ANTHONY; HAMMOND, VICTORIA JODY; WHELDRAKE, AMY NICOLE
To: T.J.SMITH AND NEPHEW,LIMITED
Reel/Frame 060689/0764 →
Priority Claims (2)
GB 1901476 · Feb 4, 2019 · national
GB 1918802 · Dec 19, 2019 · national
Continuity (1)
Related Publication 20220226536A1 · Jul 21, 2022
References Cited (57)
US 6685681B2 · Lockwood et al. · 2004 [cited by applicant]
US 8808722B2 · Scholz et al. · 2014 [cited by applicant]
US 9486553B2 · Cotton · 2016 [cited by applicant]
US 10052236B2 · Locke et al. · 2018 [cited by applicant]
US 10076586B2 · McInroy · 2018 [cited by applicant]
US 10105466B2 · Hong et al. · 2018 [cited by applicant]
US 10143485B2 · Locke et al. · 2018 [cited by applicant]
US 10370571B2 · Determan et al. · 2019 [cited by applicant]
US 10568770B2 · Robinson et al. · 2020 [cited by applicant]
US 20040241214A1 · Kirkwood · 2004 [cited by examiner]
US 20100080795A1 · Li et al. · 2010 [cited by applicant]
US 20140249495A1 · Mumby · 2014 [cited by examiner]
US 20150141941A1 · Allen · 2015 [cited by examiner]
US 20150182677A1 · Collinson et al. · 2015 [cited by applicant]
US 20160195754A1 · Zhong et al. · 2016 [cited by applicant]
US 20170204136A1 · Dhara · 2017 [cited by examiner]
US 20170231821A1 · Addison et al. · 2017 [cited by applicant]
US 20170231822A1 · Hoggarth et al. · 2017 [cited by applicant]
US 20180154003A1 · Sershen et al. · 2018 [cited by applicant]
US 20180353334A1 · Locke et al. · 2018 [cited by applicant]
US 20190117465A1 · Osborne et al. · 2019 [cited by applicant]
US 20200000630A1 · Scalzo et al. · 2020 [cited by applicant]
EP 0541391A1 · 1993 [cited by applicant]
EP 1413270B1 · 2009 [cited by applicant]
EP 2227228B1 · 2018 [cited by applicant]
WO WO9739781A1 · 1997 [cited by applicant]
WO WO0074738A1 · 2000 [cited by examiner]
WO WO2004018020A1 · 2004 [cited by applicant]
WO WO2004024196A1 · 2004 [cited by applicant]
WO WO2004096301A2 · 2004 [cited by examiner]
WO WO2006044342A2 · 2006 [cited by applicant]
WO WO2008117300A2 · 2008 [cited by applicant]
WO WO2013164016A1 · 2013 [cited by examiner]
WO WO2015140581A1 · 2015 [cited by applicant]
WO WO2016109418A1 · 2016 [cited by applicant]
WO WO2016109420A1 · 2016 [cited by applicant]
WO WO2016141450A1 · 2016 [cited by applicant]
WO WO2018108784A1 · 2018 [cited by examiner]
WO WO2018231815A2 · 2018 [cited by applicant]
WO WO2019006356A1 · 2019 [cited by applicant]
WO WO2019012069A1 · 2019 [cited by applicant]
WO WO2019209562A1 · 2019 [cited by applicant]
Lamme et al.; Cadexomer-iodine ointment shows stimulation of epidermal regeneration in experimental full-thickness wounds; Springer-Verlag; Arch Dermatol Res (1998) 290 : 18-24. (Year: 1998). [cited by examiner]
Fawcett et al.; Thermoplastic Silicone Elastomers through Self-Association of Pendant Coumarin Groups; ACS Publications; Macromolecules 2014, 47, 1656-1663 (Year: 2014). [cited by examiner]
Viscose; https://blog.ministryofsupply.com/blog/2019/9/26/viscose-the-regenerated-fiber; (site accessed Mar. 2024) (Year: 2019). [cited by examiner]
Providone-iodine; https://go.drugbank.com/drugs/DB06812 (site accessed Mar. 2024) (Year: 2020). [cited by examiner]
\Wound dressings; https://dfwwoundcarecenter.com/blog/types-of-wound-dressings-when-to-use-each/ (site accessed Mar. 2024 (Year: 2024). [cited by examiner]
Contact layers; https://www.coloplastprofessional.co.uk/products/product-information/products-wound-care/contact-layer-dressings/what-is-a-contact-layer/#sample(site accessed Mar. 2024) (Year: 2024). [cited by examiner]
International Search Report and Written Opinion for Application No. PCT/EP2020/052645, mailed on May 15, 2020, 8 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/EP2020/059249, mailed on Jun. 19, 2020, 10 pages. [cited by applicant]
Lamme E. N. et al., “Cadexomer-iodine ointment shows stimulation of epidermal regeneration in experimental full-thickness wounds,” Archives of Dermatological Research, vol. 290, Jan. 1998, pp. 18-24. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2020/059249, mailed on Oct. 21, 2021, 7 pages. [cited by applicant]
International Preliminary Report on Patentability for Application No. PCT/EP2020/052645, mailed on Aug. 19, 2021, 7 pages. [cited by applicant]
Liu., et al., “In situ forming hydrogels based on chitosan for drug delivery and tissue regeneration,” Asian Journal of Pharmaceutical Sciences, ScienceDirect, 2016, vol. 11, pp. 673-683. [cited by applicant]
Brannon-Peppas., et al., “Dynamic and equilibrium swelling behaviour of pH-sensitive hydrogels containing 2-hydroxyethyl methacrylate,” The Biomaterials Silver Jubilee Compendium, 1990, vol. 11, pp. 635-644. [cited by applicant]
Gyles D.A., et al., “A Review of the Designs and Prominent Biomedical Advances of Natural and Synthetic Hydrogel Formulations,” European Polymer Journal, Mar. 2017, vol. 88, pp. 373-392. [cited by applicant]
Moura L.I.F., et al., “Recent Advances on the Development of Wound Dressings for Diabetic Foot Ulcer Treatment—A Review,” Acta Biomaterialia, Jul. 2013, vol. 9, No. 7, pp. 7093-7114. [cited by applicant]